Novo Nordisk A/S vs Merck & Company, Inc. — Stock Comparison
Q·Score Breakdown
6.1
Hold
Overall
7.3
Buy
Quality
Health
Growth
Valuation
Sentiment
NVO
High-quality business with 61% return on equity and 33% profit margins.
⚠ revenue declining 8% year-over-year.
MRK
High-quality business with 37% return on equity and 28% profit margins.
⚠ earnings contracting 19% year-over-year.
Analyst Consensus
HOLD
Target $46.65 (+9.5%)
12 analysts
BUY
Target $129.74 (+17.0%)
27 analysts
Fundamentals
NVO
MRK
11.8×
Trailing P/E
15.2×
12.4×
Forward P/E
11.4×
33.1%
Profit Margin
28.1%
82.4%
Gross Margin
77.2%
60.7%
ROE
36.9%
-7.6%
Revenue Growth
5.0%
-4.7%
Earnings Growth
-19.3%
0.27
Beta
0.28
—
Price / Book
—
$188.9B
Market Cap
$273.9B
$35 – $81
52-Week Range
$73 – $125
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load.